Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases

被引:41
作者
van Kessel, C. S. [1 ,2 ]
Samim, M. [2 ]
Koopman, M. [3 ]
van den Bosch, A. A. J. [1 ]
Rinkes, I. H. M. Borel [1 ]
Punt, C. J. A. [4 ]
van Hillegersberg, R. [2 ]
机构
[1] Univ Med Ctr Utrecht, Dept Radiol, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Surg, NL-3584 CX Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3584 CX Utrecht, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands
关键词
Chemotherapy; Response assessment; Heterogeneity; RECIST criteria; Colorectal liver metastases; Survival; RANDOMIZED CONTROLLED-TRIAL; CANCER-GROUP DCCG; PHASE-III; COMBINATION CHEMOTHERAPY; GENETIC-HETEROGENEITY; SOLID TUMORS; CAPECITABINE; OXALIPLATIN; ADENOCARCINOMAS; BEVACIZUMAB;
D O I
10.1016/j.ejca.2013.03.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In patients with colorectal liver metastases (CLM) there is limited knowledge about the occurrence of radiological heterogeneity in response to chemotherapy. Methods: A retrospective analysis was performed in the CAIRO and CAIRO II studies on the incidence of intermetastatic heterogeneity in patients with CLM and its association with survival. Mixed response (MR) was defined as >30% difference in individual lesion response, with all lesions showing a similar behaviour; true mixed response (TMR) as two lesions showing progression versus response; homogeneous response (HR) as similar behaviour of all lesions. Patients were classified according to the Response Evaluation Criteria in Solid Tumours (RECIST) categories (partial response (PR), stable disease (SD), progressive disease (PD), complete response (CR)) and then subdivided into MR and TMR in order to compare survival. Results: In the CAIRO and CAIRO II studies, 140 and 150 patients with liver-only disease were identified. 73/290 (25.2%) patients showed MR, and 25/290 (8.6%) patients TMR, and 192/290 (66.2%) patients HR. Overall survival (OS) at 1-4 years was significantly higher for the homogeneous partial responders category compared to other response categories. Median OS was 22.0 months for the entire population. In the partial response category, patients with MR showed significant poorer survival compared to patients with HR (median OS 23.7 versus 36.0 months, respectively, p = 0.019). Multivariate analysis identified four independent predictors for OS: serum lactate dehydrogenase (LDH) level (p = 0.002), number of first-line chemotherapy cycles (p = 0.001), resection of primary tumour (p = 0.001) and response category (p = 0.012). Conclusion: Radiological heterogeneity is present in approximately 35% of patients with CLM. Partial responders according to the RECIST criteria, show a significant poorer survival if classified as heterogeneous partial responder compared to homogeneous partial responders. (c) 2013 Published by Elsevier Ltd.
引用
收藏
页码:2486 / 2493
页数:8
相关论文
共 28 条
[1]  
Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO
[2]  
2-M
[3]   Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma [J].
Baisse, B ;
Bouzourene, H ;
Saraga, EP ;
Bosman, FT ;
Benhattar, J .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (03) :346-352
[4]  
Bläker H, 1999, J PATHOL, V188, P258, DOI 10.1002/(SICI)1096-9896(199907)188:3<258::AID-PATH350>3.0.CO
[5]  
2-9
[6]   Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J].
Buyse, M ;
Thirion, P ;
Carlson, RW ;
Burzykowski, T ;
Molenberghs, G ;
Piedbois, P .
LANCET, 2000, 356 (9227) :373-378
[7]   Worldwide Variations in Colorectal Cancer [J].
Center, Melissa M. ;
Jemal, Ahmedin ;
Smith, Robert A. ;
Ward, Elizabeth .
CA-A CANCER JOURNAL FOR CLINICIANS, 2009, 59 (06) :366-378
[8]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[9]  
Giaretti W, 1996, AM J PATHOL, V149, P237
[10]  
Giovagnoli MR, 1999, ANTICANCER RES, V19, P4577